Genmab — November 2017
-
From the Halozyme Therapeutics Q3 Results - Earnings Call Transcript:
https://seekingalpha.com/article/4122004-halozyme-therapeutics-halo-ceo-dr-helen-torley-q3-2017-results-earnings-call-transcript?part=single -
Based on these results, Janssen has finalized a 15 ml injection of co-formulated daratumumab plus rHuPH20 to be delivered in five minutes or less and the dose of first amyloidosis patient in the Phase 3 trial. This is the first of three Phase 3 studies Janssen plans to initiate in the near-term. The others will be in multiple myeloma and in smaller in myeloma patients. Upon the dosing of the third patient, Halozyme will earn a $15 million milestone payment.
-
As we’ve been demonstrated previously, once the partner begins the Phase 3 study using our technology, approval has been ultimately granted by the applicable regulatory agency in all cases whereof three for three, and therefore view the star of the daratumumab Phase 3 trial as a meaningful de-risking event for the combination. To finish in DARZALEX, market receptions to the IV formulation remain strong.
-
Q: So first, any idea how quickly Janssen can move into Phase 3 for multiple myeloma and smouldering myeloma?
Dr. Helen Torley
Well, certainly for multiple myeloma, the previously made comments that it will happen before the end of this year. So I do think absolutely in the next weeks for the multiple myeloma study. I don’t think this given the specific from the smouldering myeloma, but we know they’re working all three of the studies in parallel. So, it will begin soon as well.
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind